文献速递心力衰竭与心肌病

糖类抗原125在射血分数保留心力衰竭诊断中的价值评估

Evaluation of carbohydrate antigen 125 in heart failure with preserved ejection fraction diagnosis.
PubMed 文献 · Heart · 2026-01-27

本研究为前瞻性多中心研究,纳入210例临床疑似心衰的门诊患者,评估CA125对HFpEF的诊断性能。结果显示CA125与NT-proBNP的AUC相当(0.715 vs 0.765,p=0.323),CA125最佳切点12.2 U/mL,高特异性水平(>23 U/mL)阳性预测值达80.8%,低水平(<9 U/mL)阴性预测值达85.7%。

要点

  • CA125对HFpEF诊断的AUC为0.715,与NT-proBNP(0.765)相当。
  • CA125>23 U/mL特异性97%、阳性预测值80.8%,可辅助确认HFpEF。
  • CA125<9 U/mL阴性预测值85.7%,有助于排除HFpEF。

核心结论

  • 在门诊疑似心衰人群中,CA125对HFpEF具有可接受的诊断性能,可能作为NT-proBNP的补充。

研究设计与样本

  • 前瞻性多中心研究,连续纳入246例临床疑似心衰患者。
  • 排除LVEF<50%(n=8)及恶性肿瘤病史(n=22)后,最终分析210例。

主要发现

  • 研究队列平均年龄69.7±15岁,女性占69%。
  • NT-proBNP中位数125 pg/mL(IQR 51-332),CA125中位数11 U/mL(IQR 8-17)。
  • 65例(31%)诊断为HFpEF。
  • CA125诊断HFpEF的AUC为0.715(95%CI 0.636-0.793),NT-proBNP为0.765(95%CI 0.686-0.843),两者比较p=0.323。
  • CA125最佳切点12.2 U/mL(敏感性0.69,特异性0.68);NT-proBNP最佳切点243 pg/mL(敏感性0.65,特异性0.83)。

关键数值与推荐

  • CA125>23 U/mL(占样本12.4%)特异性0.97,阳性预测值80.8%,正确分类77.1%的病例为HFpEF。
  • CA125<9 U/mL的阴性预测值为85.7%。

临床怎么用

  • 在门诊疑似HFpEF患者中,可检测CA125辅助诊断,高值(>23 U/mL)支持HFpEF,低值(<9 U/mL)有助于排除。
  • CA125可与NT-proBNP联合使用,提升诊断准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current evidence supports the role of circulating carbohydrate antigen 125 (CA125) in risk assessment, disease monitoring and therapeutic guidance in heart failure (HF). However, there is limited data on its diagnostic applicability. This study aimed to assess the diagnostic performance of CA125 in identifying HF with preserved ejection fraction (HFpEF) in an outpatient population. METHODS: This was a prospective, multicentre study involving 246 consecutive patients with clinically suspected HF. Patients with a left ventricular ejection fraction <50% (n=8) and those with a history of malignancy (n=22) were excluded. The final study cohort comprised 210 patients. The diagnosis of HFpEF was confirmed by a trained cardiologist blinded to the biomarker levels. RESULTS: The mean age of the study cohort was 69.7±15 years, and 69% were women. Median levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CA125 were 125 pg/mL (IQR: 51-332) and 11 U/mL (IQR: 8-17), respectively. HFpEF was diagnosed in 65 (31%) patients. For HFpEF diagnosis, NT-proBNP and CA125 levels demonstrated comparable areas under the receiver operating characteristic curves 0.765 (95% CI: 0.686 to 0.843) vs 0.715 (95% CI: 0.636 to 0.793), respectively (p=0.323). Optimal cut points were identified as 12.2 U/mL for CA125 (sensitivity: 0.69; specificity: 0.68) and 243 pg/mL for NT-proBNP (sensitivity: 0.65; specificity: 0.83). Elevated CA125 levels (>23 U/mL, 12.4% of the sample) exhibited high specificity (0.97), a positive predictive value of 80.8% and correctly classified 77.1% of cases as HFpEF. Conversely, CA125 levels<9 U/mL were associated with a high negative predictive value (85.7%). CONCLUSION: In an ambulatory setting, CA125 exhibits acceptable diagnostic performance for identifying HFpEF and may complement NT-proBNP in clinical practice.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. de Juan Bagudá J, Severo Sánchez A, de la Espriella R, et al. Evaluation of carbohydrate antigen 125 in heart failure with preserved ejection fraction diagnosis. Heart. 2026. PMID: 40877030. doi:10.1136/heartjnl-2025-326053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。